Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York.
康涅狄格州紐哈芬，2024年11月27日（環球新聞）-- arvinas公司（納斯達克：ARVN），一家臨床階段的生物技術公司，正在創建基於靶向蛋白質降解的新藥物類別，今天宣佈首席醫療官Noah Berkowitz萬.D.博士和首席財務官Andrew Saik將於12月3日（星期二）東部時間下午2:30在紐約參加派傑投資第36屆年度醫療會議的爐邊談話。
A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website.
演示的現場音頻網絡直播將可在這裏以及公司的網頁的活動與演講部分獲取。
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X.
關於arvinas
arvinas（納斯達克:ARVN）是一家臨床階段的生物技術公司，致力於改善患有嚴重和危及生命的疾病的患者生活。通過其PROTAC（PROteolysis TArgeting Chimera）蛋白降解平台，該公司正在開拓蛋白質降解療法的發展，旨在利用人體天然蛋白質清除系統，選擇性和高效地降解和清除導致疾病的蛋白質。Arvinas目前正在推進多個處於臨床開發階段的研究藥物，包括針對局部晚期或轉移性ER+/HER2-乳腺癌患者的vepdegestrant；針對復發/難治性非霍奇金淋巴瘤患者的BCL6的ARV-393；以及針對神經退行性疾病中LRRK2的ARV-102。Arvinas總部位於康涅狄格州紐黑文。有關Arvinas的更多信息，請訪問其網站，並在LinkedIn和X上關注。
Contacts
聯繫方式
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
投資者:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
媒體:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
譯文內容由第三人軟體翻譯。
